

# ADJUVANT THERAPY IN BASAL CELL CARCINOMA: VISMODEGIB PLUS CRYOTHERAPY

David A. Castillo<sup>1</sup>, Luisa F. Camacho<sup>1</sup>, Jeanne Hernandez <sup>1</sup>, Alba Pacheco<sup>1</sup>,  
Jesús D. Fierro<sup>1</sup>, María C. Velásquez-Vargas<sup>1</sup>, Paula A. Chacón<sup>1</sup>, Luisa F. Baez<sup>1</sup>

1. Fundación para la investigación en dermatología – Funinderma. Bogotá, Colombia.

- The authors declare that they have no conflict of interest -



18<sup>th</sup> World Congress  
on Cancers of the Skin  
Buenos Aires, Argentina  
WCCS 2022 Hybrid Congress  
October 26-29, 2022

wccs2022.com

E-poster responsible  
David Castillo Molina  
Colombia  
davidcastillomolina@gmail.com



Fundación para  
la investigación  
en Dermatología

## Introduction

Although most BCC is curable by surgery and/or radiotherapy, nevertheless locally-advanced BCC (laBCC) and metastatic BCC (mBCC) are best addressed through systemic therapy.<sup>1</sup> Vismodegib is an inhibitor of the Hedgehog pathway preventing its aberrant activation, approved for locally advanced and metastatic BCC treatment not suitable for surgery.<sup>2</sup> On the other hand, cryotherapy has been described for low-risk BCC being efficient as surgery.<sup>3</sup> In this study, we reported the results of three cases with BCC treated with Vismodegib and cryotherapy who assisted a dermatological center in Bogotá, Colombia.

### References

1. Frampton JE, Basset-Séguin N. Vismodegib: A Review in Advanced Basal Cell Carcinoma. *Drugs*. 2018;78(11):1145-1156.
2. Basset-Séguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. *Eur J Cancer*. 2017;86:334-348.
3. Tchanque-Fossuo, C. N, & Eisen, D. B. (2018). A systematic review on the use of cryotherapy versus other treatments for basal cell carcinoma. *Dermatology Online Journal*, 24(11).



## Case #1

A 66-year-old, man, 2-years history of an erythematous ulcerated plaque (2.5 x 2.5 cm) with pearly edges, with progressive growth that involves the nasal dorsum up to the left internal canthus. Associated occasional epiphora, tissue retraction, and itching. Treatment: Vismodegib 150 mg daily for 7 months and 10 sessions of cryotherapy.



Before



After

## Case #2

An 86-year-old, female, 5-years history of non-healing plaque (3 cm × 2.5 cm) which progressively grew compromising the nasal ala lateral surface of the right nostril. She received 1 month of Vismodegib 150 mg daily and 3 sessions of cryotherapy, showing an important reduction of the tumor.



Before



After

### Case #3

A 58-year-old, man, 3-years history of a progressive growth papule in upper left eyelid until it was transformed into an ulcerated tumor (3 cm x2 cm), associated with occasional itching and bleeding. Treatment: Vismodegib 150 mg daily for 6 months and received 4 sessions of cryotherapy, showing adequate reduction of lesion's size.



Before



After

## Conclusions

Patients with locally advanced BCC who are not suitable for surgery are a challenge in clinical practice. Vismodegib is an alternative that shows a clinical improvement from 6 to 9.5 months.<sup>4</sup> We found an adequate and faster response in our patients using cryotherapy as an adjuvant for Vismodegib, diminishing costs. Although evidence regarding a combined therapy between these two treatments was not found, it could be considered as a strategy for these conditions. Future studies are necessary for confirming these results.

### References

4. Meiss F, Andrlová H, Zeiser R. Vismodegib. In: Martens UM, ed. *Small Molecules in Oncology*. Cham: Springer International Publishing; 2018:125-139.

